818 Recruiting Trials

Clinical Trials
in Oklahoma

Browse 818 recruiting clinical trials currently enrolling participants in Oklahoma. Search by condition to find trials you may qualify for, at no cost.

Showing 15 of 818 recruiting trials in Oklahoma

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
N/A Birmingham, Alabama +4 sites · Solid Tumor, Leukemia
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
N/A Athens, Alabama +4 sites · Lumbar Spinal Stenosis
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
PHASE1 La Jolla, California +4 sites · Colorectal Cancer, Esophageal Cancer
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
PHASE3 Anchorage, Alaska +4 sites · Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
PHASE3 Birmingham, Alabama +4 sites · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Recruiting
Recruiting
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
PHASE2 Anchorage, Alaska +4 sites · Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Recruiting
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
PHASE2 Phoenix, Arizona +4 sites · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Recruiting
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
PHASE3 Birmingham, Alabama +4 sites · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Recruiting
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
PHASE2 Dublin, California +4 sites · Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Recruiting